At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma

* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. * The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...